AURA (Aura Biosciences, Inc. Common Stock) Stock Analysis - News
Aura Biosciences, Inc. Common Stock (AURA) is a publicly traded Healthcare sector company. As of May 21, 2026, AURA trades at $8.00 with a market cap of $772.30M and a P/E ratio of -4.26. AURA moved +1.15% today. Year to date, AURA is +44.21%; over the trailing twelve months it is +25.97%. Its 52-week range spans $4.35 to $12.38. Analyst consensus is strong buy with an average price target of $19.75. Rallies surfaces AURA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in AURA news today?
Aura Biosciences Raises $299 Million, Extends Cash Runway into 2H 2028: Aura Biosciences advanced its Phase 3 CoMpass trial toward mid-2026 enrollment completion, targeting second-half 2027 topline data for bel-sar in early choroidal melanoma. It also secured $299 million in oversubscribed equity financing and appointed Natalie Holles as CEO, funding operations into the second half of 2028.
Aura Biosciences Raises $299 Million, Extends Cash Runway into 2H 2028: Aura Biosciences advanced its Phase 3 CoMpass trial toward mid-2026 enrollment completion, targeting second-half 2027 topline data for bel-sar in early choroidal melanoma. It also secured $299 million in oversubscribed equity financing and appointed Natalie Holles as CEO, funding operations into the second half of 2028.
Does Rallies summarize AURA news?
Yes. Rallies summarizes AURA news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is AURA research on Rallies investment advice?
No. Rallies provides research, data, and educational context for AURA. It does not provide personalized investment advice.
